Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Collateral likes the angiogenesis treadmill

Although Chiron Corp. may have concluded that treadmill exercise time might not be the best end point for testing angiogenesis compounds in cardiovascular conditions, Collateral Therapeutics Inc. believes that the treadmill has successfully pointed it toward pivotal studies of its gene therapy for angina.

CHIR's fibroblast growth factor-2

Read the full 479 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE